# Pseudoexfoliation Syndrome and Glaucoma

Pseudoexfoliation syndrome requires structured surveillance for asymmetric, pressure-labile glaucoma and deliberate cataract planning because zonular weakness, poor dilation, endothelial vulnerability, and postoperative pressure elevation materially alter treatment selection and surgical risk.

**Clinical question:** How should physicians evaluate, treat, and monitor glaucoma risk in pseudoexfoliation syndrome?

Updated: 2026-08-21T01:50:03.563939+00:00

## What matters in practice
- Pseudoexfoliation syndrome is an independent risk factor for glaucoma and is associated with cataract formation; assess each affected eye for pressure elevation and glaucomatous structural and functional injury.[1][4][10]
- Use gonioscopy, optic nerve assessment, OCT, and perimetry to distinguish pseudoexfoliation without glaucoma from pseudoexfoliative glaucoma and to identify coexisting narrow-angle anatomy.[2][12][22]
- Escalate pressure-lowering therapy, SLT, or incisional surgery when IOP remains above the individualized level needed to prevent structural or functional progression; pseudoexfoliative glaucoma often warrants closer follow-up and more aggressive treatment.[18]
- Before cataract surgery, identify poor dilation, phacodonesis or lens subluxation, and zonular instability; these predict technically difficult surgery and complications including zonular dialysis, capsular rupture, postoperative IOP spikes, and late IOL decentration.[18][23]

## Separate pseudoexfoliation syndrome from established glaucoma and angle disease

The immediate decision is whether the eye has pressure-mediated optic neuropathy, a narrow-angle component, or cataract-related surgical risk.

Treat pseudoexfoliation material as a high-risk ocular finding rather than a diagnosis of glaucoma by itself. Pseudoexfoliation is associated with increased glaucoma risk independent of other recognized glaucoma risk factors, including IOP, while individual clinical trajectories range from no glaucoma to severe vision loss.[4][8] Document laterality, IOP in each eye, optic disc appearance, and whether glaucomatous visual field loss or retinal nerve fiber layer injury is present before assigning pseudoexfoliative glaucoma.

Perform gonioscopy rather than presuming a purely open-angle mechanism. Pseudoexfoliation is associated with narrow angles secondary to zonular weakness; cataract or anterior lens movement from zonular laxity can contribute to angle closure and changes management toward lens-based treatment or laser iridoplasty when appropriate.[18][22] A painful red eye with sudden visual decline should trigger urgent evaluation for acute angle closure rather than routine chronic-glaucoma follow-up.[5]

Establish a structural-functional baseline with slit-lamp biomicroscopy of the anterior and posterior segments, stereoscopic optic nerve examination, OCT of the optic nerve/RNFL, and standard automated perimetry. OCT, perimetry, and gonioscopy are core glaucoma assessment modalities, and longitudinal visual-field change plus optic nerve examination should drive treatment intensification rather than IOP alone.[12][16]
- At every baseline or progression visit, record Goldmann applanation IOP, gonioscopic angle configuration, optic nerve head findings, OCT/RNFL result, and visual-field status.[2][12][16]
- Look specifically for coexisting cataract, inadequate dilation, lens instability, corneal endothelial compromise, and signs of prior or current glaucomatous damage because each changes procedural planning.[18]

*Clinical branch points in an eye with pseudoexfoliation material.[4][18][22]*

| Clinical pattern | Key discriminator | Next action |
| --- | --- | --- |
| Pseudoexfoliation syndrome without demonstrable glaucomatous injury | Pseudoexfoliation material with no established optic nerve or visual-field damage | Obtain baseline IOP, gonioscopy, OCT, and perimetry; continue at least annual examination for ocular hypertension or glaucoma detection.[18] |
| Pseudoexfoliative glaucoma | Pseudoexfoliation plus elevated IOP and glaucomatous structural and/or functional progression | Set an individualized pressure-lowering goal and advance topical treatment, SLT, or surgery if control is insufficient.[18] |
| Narrow-angle or lens-related component | Gonioscopic narrowing with cataract or anterior lens movement related to zonular laxity | Assess for laser iridoplasty or cataract extraction; plan cataract surgery for zonular risk.[18][22] |
| Acute angle closure phenotype | Eye pain and sudden visual decrease with acute high IOP syndrome | Arrange urgent ophthalmic management for acute angle closure rather than outpatient surveillance.[5] |

## Lower IOP when pseudoexfoliative glaucoma is present or progression risk requires treatment

No therapy halts pseudoexfoliation material deposition; treatment is directed at IOP and documented glaucomatous progression.

There is no treatment that stops pseudoexfoliation material deposition. In pseudoexfoliative glaucoma, choose therapy according to the pressure reduction required, treatment tolerance, angle anatomy, cataract status, and evidence of structural or field progression.[18] IOP lowering is the modifiable intervention used to alter glaucoma progression, with topical agents, laser treatment, and drainage surgery constituting the principal options.[21]

A prostaglandin analog is a common first-line topical approach for open-angle glaucoma. FDA-approved drug classes include prostaglandin analogs, topical carbonic anhydrase inhibitors, beta-blockers, cholinergic agents, and other IOP-lowering therapies; select based on ocular and systemic contraindications rather than class escalation by habit.[20] Avoid nonselective topical beta-blockers in asthma or COPD and also consider heart block, hypotension, and bradycardia.[24]

When topical treatment is not tolerated, assess preservative-related ocular surface disease and simplify the regimen before abandoning pressure control. Transitioning to preservative-free formulations or formulations with less cytotoxic preservatives can improve ocular surface symptoms; persistent medication intolerance can justify earlier SLT or surgery, depending on pressure and progression risk.[19]
- Reassess adherence, ocular-surface toxicity, IOP response, optic nerve status, OCT, and visual field before concluding that a medication has failed.[16][19]
- Use systemic carbonic anhydrase inhibitors primarily for acute IOP elevation or when topical therapy cannot be used; they are not routine chronic first-line therapy.[24]
- Use caution with corticosteroids in patients at risk for glaucoma because steroid exposure can contribute to secondary open-angle glaucoma.[17][20]

### Selective laser trabeculoplasty

Consider 360° SLT for eligible open-angle disease when a laser-based approach can achieve the required IOP reduction or when drops are poorly tolerated. NICE recommends 360° SLT as first-line treatment for newly diagnosed chronic open-angle glaucoma and for ocular hypertension with IOP of at least 24 mm Hg in patients at lifetime risk of visual impairment; pseudoexfoliation was not explicitly excluded, although trial representation was limited.[14]

Counsel that post-laser inflammation and transient IOP elevation can occur. If IOP remains insufficiently reduced after SLT, pharmacotherapy, or both, proceed to discussion of incisional options rather than continuing ineffective serial medication changes.[16][21]

*IOP-lowering modality selection in pseudoexfoliative glaucoma.[14][18][19][21][24]*

| Modality | When it is useful | Important limitation or precaution |
| --- | --- | --- |
| Topical prostaglandin analog | Common first-line therapy for open-angle glaucoma when topical treatment is acceptable.[21] | Monitor for hypertrichosis, iris pigmentation change, and prostaglandin-associated periorbitopathy.[21] |
| Topical beta-blocker | Alternative or adjunct when systemic status permits.[16][24] | Avoid nonselective agents in asthma or COPD; also avoid or use great caution with bradycardia, hypotension, or heart block.[24] |
| 360° SLT | Eligible chronic open-angle glaucoma or ocular hypertension; can reduce dependence on drops.[14] | Evidence in pseudoexfoliation was limited in the cited trial base; inflammation and IOP spikes may occur.[14][21] |
| Incisional glaucoma surgery | Progression or inadequate IOP reduction despite maximal medical therapy and/or SLT.[18] | Balance lower IOP needs against hypotony, bleb-related complications, tube erosion, endophthalmitis, and corneal decompensation risks.[20][21] |

## Escalate to glaucoma surgery when target pressure cannot be achieved

Persistent progression or inadequate IOP control after topical therapy and/or SLT warrants procedure selection based on target pressure and anatomy.

Consider trabeculectomy after maximal tolerated medical treatment and/or SLT fail to control pseudoexfoliative glaucoma. Reported trabeculectomy outcomes in pseudoexfoliative glaucoma are similar to those in primary open-angle glaucoma without an increased complication rate, but postoperative drops may still be necessary if the achieved target pressure is not low enough.[18]

Glaucoma drainage devices, canaloplasty, and viscocanalostomy are alternatives in selected eyes. MIGS remains a context-dependent choice: it may reduce medication burden, but its ability to reach very low target pressures is less certain than traditional filtration surgery, and the broader role of MIGS remains controversial.[18][20][21]

Reserve cyclodestructive approaches for appropriate refractory disease; cyclocryotherapy is described as a treatment for painful eyes with vision loss from glaucoma. Procedure choice should be driven by visual potential, target IOP, prior surgery, conjunctival status, and the need to avoid or accept a filtering bleb.[24]
- Do not delay surgical discussion when serial OCT or visual fields show progression despite apparently acceptable clinic IOP; the individualized target must be lowered when damage continues.[16][18]
- Discuss bleb-related complications before trabeculectomy and tube erosion, endophthalmitis, and corneal decompensation before tube shunt surgery.[20][21]

*Procedure-level tradeoffs for inadequately controlled pseudoexfoliative glaucoma.[18][20][21][24]*

| Procedure category | Potential role | Principal decision tradeoff |
| --- | --- | --- |
| Trabeculectomy | Failure of maximal medical therapy and/or SLT; excellent IOP control is a recognized advantage.[18][20] | Requires bleb management and carries bleb-related complication risk.[20] |
| Glaucoma drainage device | Alternative for selected refractory eyes.[18] | Potential complications include tube erosion, endophthalmitis, and corneal decompensation.[21] |
| Canaloplasty or viscocanalostomy | Alternative nonfiltering procedures in selected pseudoexfoliative glaucoma.[18] | May not achieve sufficiently low target pressure; adjunct drops can remain necessary.[18] |
| Cyclodestructive treatment | Refractory glaucoma or painful eye with vision loss, depending on technique.[24] | Use when visual potential and treatment goals justify destructive reduction of aqueous production.[24] |

## Plan cataract surgery as a high-risk zonular procedure

Pseudoexfoliation changes preoperative assessment, intraoperative preparedness, and postoperative pressure surveillance.

Before cataract extraction, document dilation quality, phacodonesis, lens subluxation, corneal status, baseline IOP, and glaucoma severity. Pseudoexfoliation affects the anterior segment, including iris, zonules, and cornea, and is associated with increased cataract frequency; zonular detachment can occur through mechanical forces or enzymatic zonulolysis.[10][11][23]

Anticipate poor mydriasis and zonular instability. Pseudoexfoliation-associated cataract surgery complications include corneal edema, capsular phimosis, inflammation, zonular dialysis, capsular bag rupture, postoperative IOP spikes, and late IOL decentration; lens subluxation and corneal endothelial disease further increase operative complexity.[18]

If gonioscopy suggests a lens-related angle component, cataract extraction may be beneficial, but it should not be viewed as a substitute for glaucoma surgery when the required target IOP is lower than lens extraction is likely to provide. Coordinate the cataract and glaucoma procedural plan around degree of optic neuropathy, pressure control, and zonular support needs.[18][20]
- Use preoperative counseling to explain that pseudoexfoliation increases the likelihood of intraoperative zonular and dilation problems and late IOL-bag complex instability.[18][23]
- Check IOP after cataract surgery because postoperative pressure spikes are a recognized complication in pseudoexfoliation eyes.[18]
- Continue glaucoma surveillance after uncomplicated lens extraction; pseudoexfoliation material deposition is not eliminated by cataract surgery.[18]

*Cataract-surgery risk assessment in pseudoexfoliation syndrome.[18][23]*

| Finding before surgery | Why it matters | Operative or postoperative implication |
| --- | --- | --- |
| Poor pharmacologic dilation | Pseudoexfoliation is associated with poor mydriasis.[18] | Plan for challenging capsulorhexis and iris management.[18] |
| Phacodonesis, lens subluxation, or zonular weakness | Zonular detachment and instability can occur in pseudoexfoliation.[18][23] | Prepare for zonular support strategies and counsel about capsular complications and late IOL decentration.[18] |
| Corneal endothelial compromise | Corneal endotheliopathy is reported in pseudoexfoliation eyes.[18] | Recognize increased risk of postoperative corneal edema.[18] |
| Established glaucoma or elevated baseline IOP | Postoperative IOP spikes are reported after cataract surgery in pseudoexfoliation.[18] | Arrange postoperative IOP surveillance and maintain a separate glaucoma-control plan.[18] |

## Monitor more closely when IOP is elevated or structural and functional damage is progressing

Follow-up intensity should track IOP control, optic nerve vulnerability, visual-field change, treatment burden, and planned surgery.

At minimum, eyes with pseudoexfoliation require annual examination to detect ocular hypertension or glaucoma. Increase visit frequency when IOP is elevated, when OCT or visual field testing shows progression, after treatment changes, or when cataract surgery is planned or recently completed.[18]

Use serial IOP, visual fields, and stereoscopic optic nerve examination to determine whether the current target is adequate. Glaucoma monitoring decisions should incorporate risk factors for conversion and sight loss, coexisting pathology, and detectable changes in visual field or optic nerve status.[16]

Counsel that pseudoexfoliation is progressive and that glaucoma risk differs between eyes and over time. Prompt reassessment is warranted for new pain or abrupt visual loss because that presentation is incompatible with routine asymptomatic surveillance and raises concern for acute angle closure.[5][9]
- After initiating or changing therapy, document IOP response and treatment tolerance before the next escalation decision.[16][19]
- After SLT, monitor for intraocular inflammation and IOP elevation.[21]
- After filtering or tube surgery, monitor for hypotony, cataract, surgical failure, infection-related complications, and corneal compromise.[21]

*Monitoring triggers that should change management in pseudoexfoliation syndrome.[5][16][18][21]*

| Finding | Interpretation | Action |
| --- | --- | --- |
| New OCT/RNFL loss or repeatable visual-field progression | Current IOP level is not adequately preventing damage.[16] | Lower the treatment target and add or advance topical therapy, SLT, or surgery.[16][18] |
| IOP elevation despite prescribed therapy | Insufficient pharmacologic response, adherence problem, or need for procedural escalation.[16][18] | Review administration and tolerance; consider SLT or incisional surgery when control remains inadequate.[16][18] |
| Post-SLT inflammation or IOP spike | Recognized laser complication.[21] | Perform post-procedure IOP and inflammation assessment and treat according to severity.[21] |
| Eye pain with sudden visual decline | Possible acute angle-closure event.[5] | Arrange urgent ophthalmic evaluation.[5] |

## References
1. Association of Pseudoexfoliation With Systemic Vascular ... — jamanetwork.com — https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2609102
2. The Characteristics of Glaucoma in Japanese Americans — jamanetwork.com — https://jamanetwork.com/journals/jamaophthalmology/fullarticle/421031
3. Exfoliation Syndrome in Black South Africans | Glaucoma — jamanetwork.com — https://jamanetwork.com/journals/jamaophthalmology/fullarticle/415399
4. The Relationship Between Glaucoma and Pseudoexfoliation — jamanetwork.com — https://jamanetwork.com/journals/jamaophthalmology/fullarticle/412473
5. Glaucoma — www.thelancet.com — https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)61423-7/fulltext
6. Prediction of structural glaucoma progression from ... — www.thelancet.com — https://www.thelancet.com/journals/landig/article/PIIS2589-7500(26)00055-5/fulltext?dgcid=icw_podcast_acq-july26_landig
7. Systematic Review of Clinical Practice Guidelines... : Journal of Glaucoma — journals.lww.com — https://journals.lww.com/glaucomajournal/fulltext/2026/02000/systematic_review_of_clinical_practice_guidelines.2.aspx
8. A Multitrait Open-Angle Glaucoma Polygenic Risk Score ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0161642025001344
9. Current understanding of genetics and epigenetics in ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0098299723000547
10. Pseudoexfoliation and the cataract surgeon: Preoperative, ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0886335009003083
11. Pseudoexfoliation - an overview — www.sciencedirect.com — https://www.sciencedirect.com/topics/medicine-and-dentistry/pseudoexfoliation
12. Glaucoma | Training in Ophthalmology - Oxford Academic — academic.oup.com — https://academic.oup.com/book/24654/chapter/188036449
13. Guideline Glaucoma: diagnosis and management — www.nice.org.uk — https://www.nice.org.uk/guidance/ng81/update/ng81-update-1/documents/draft-guideline-2
14. Glaucoma: diagnosis and management — www.nice.org.uk — https://www.nice.org.uk/guidance/ng81/evidence/january-2022-evidence-review-for-selective-laser-trabeculoplasty-in-ocular-hypertension-or-chronic-openangle-glaucoma-adult-patients-pdf-10951196077
15. HTG470 Microinvasive subconjunctival insertion of a trans- ... — www.nice.org.uk — https://www.nice.org.uk/guidance/htg470/evidence/overview-final-pdf-4839398749
16. Recommendations | Glaucoma: diagnosis and management  | Guidance | NICE — www.nice.org.uk — https://www.nice.org.uk/guidance/ng81/chapter/recommendations
17. Assessment report - Rhokiinsa - European Medicines Agency — www.ema.europa.eu — https://www.ema.europa.eu/en/documents/assessment-report/rhokiinsa-epar-public-assessment-report_en.pdf
18. Pseudoexfoliation Syndrome and Glaucoma - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK574522
19. Managing Ocular Surface Disease in Glaucoma Treatment: A Systematic Review — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC11504873
20. Updates on the Diagnosis and Management of Glaucoma — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC9673042
21. Normal Tension Glaucoma - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK576377
22. The Medical and Surgical Management of Pseudoexfoliation ... — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC2632880
23. Cataract Surgery and Possible Complications in Patients with ... — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC5389488
24. Open Angle Glaucoma - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK441887

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.